Provided by Tiger Trade Technology Pte. Ltd.

BioAtla, Inc.

0.1733
-0.0957-35.58%
Post-market: 0.1651-0.0082-4.73%19:58 EST
Volume:14.00M
Turnover:2.45M
Market Cap:11.00M
PE:-0.15
High:0.2501
Open:0.2500
Low:0.1400
Close:0.2690
52wk High:1.43
52wk Low:0.1400
Shares:63.46M
Float Shares:50.38M
Volume Ratio:7.13
T/O Rate:27.79%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1495
EPS(LYR):-1.4365
ROE:-813.88%
ROA:-105.08%
PB:-0.35
PE(LYR):-0.12

Loading ...

BioAtla Inc. Announces Date for Upcoming Special Meeting of Stockholders

Reuters
·
Jan 31

BioAtla Pursues Share Consolidation Amid Nasdaq Compliance Dispute

TIPRANKS
·
Jan 31

BioAtla files $200M mixed securities shelf

TIPRANKS
·
Jan 17

Bioatla Inc : Files for Mixed Shelf Offering of up to $200 Mln - SEC Filing

THOMSON REUTERS
·
Jan 17

BioAtla initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
Jan 14

BioAtla Creates Super-Voting Share to Advance Reverse Split

TIPRANKS
·
Jan 13

BioAtla Inc. Held Special Shareholder Meeting

Reuters
·
Jan 13

BioAtla Partners with Inversagen AI to Advance Oz-V Senolytic Therapy for OPSCC

Reuters
·
Dec 31, 2025

Bioatla and Gatc Health Announce a $40 Million Special Purpose Vehicle (Spv) Transaction to Advance Ozuriftamab Vedotin (Oz-V) Into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (Opscc)

THOMSON REUTERS
·
Dec 31, 2025

Bioatla Inc: to Retain 65% Ownership of Oz-V Across All Solid Tumor Indications After Completion of Spv Transaction

THOMSON REUTERS
·
Dec 31, 2025

Bioatla Inc: Phase 3 Trial Execution for Oz-V Enrollment Anticipated to Begin Early 2026

THOMSON REUTERS
·
Dec 31, 2025

Bioatla Inc: Co & Gatc Health to Collaborate With Inversagen AI for Research and Development of Cab Senolytic Therapies

THOMSON REUTERS
·
Dec 31, 2025

Bioatla Inc: Will Lead Phase 3 Trial Execution for Oz-V in Opscc Through Data Readout for Potential Accelerated Approval

THOMSON REUTERS
·
Dec 31, 2025

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

GlobeNewswire
·
Dec 31, 2025

BioAtla Inc. Held Special Shareholder Meeting

Reuters
·
Dec 31, 2025

BioAtla Inc. Announces Date for Upcoming Special Meeting of Stockholders

Reuters
·
Nov 25, 2025

BioAtla Secures $7.5 Million Pre-Paid Advance Financing from Yorkville and Anson Funds

Reuters
·
Nov 21, 2025

BioAtla Agrees to $22.5 Million in Financing Agreements

MT Newswires Live
·
Nov 21, 2025

Bioatla Enters Into Agreements for up to $22.5 Million Flexible Financing

THOMSON REUTERS
·
Nov 21, 2025

Press Release: BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

Dow Jones
·
Nov 21, 2025